A new cleavable linker based on a cyclic β-diketone scaffold enables selective payload release inside tumor cells, demonstrated through both a peptide-drug conjugate and an antibody-drug conjugate targeting EGFR.
Dde linkernew cleavable scaffold for peptide-drug and antibody-drug conjugates with selective intracellular release
What the researchers found
A cyclic α-alkylidene-β-diketone linker with azido trigger provides selective intracellular drug release, demonstrated through EGFR-targeting peptide-drug and antibody-drug conjugates.
Why it matters
ADCs are among the fastest-growing classes of cancer therapy. Better linker chemistry directly translates to safer, more effective treatments by ensuring drugs stay attached during circulation but release efficiently inside tumor cells.
The numbers in context
Study explored Dde-based linker chemistry for ADC construction (specific numerical results not provided in abstract excerpt).
How the study worked
Chemical synthesis and characterization of Dde-based cleavable linker, conjugation to EGFR-targeting peptide and antibody, with assessment of stability and release under reducing conditions.
Who was studied
Chemical synthesis study — no human or animal subjects
What this study cannot tell us
In vitro characterization without in vivo efficacy or toxicity data; single target (EGFR) tested; comparative advantage over existing linkers (Val-Cit, SMCC) not quantified; scalability and manufacturing considerations not addressed.
How to read the evidence
Preliminary chemical proof-of-concept. Novel linker technology demonstrated in vitro but lacking in vivo validation.
When this study was published
Published in 2024, contributing to the rapidly evolving ADC and peptide-drug conjugate design field.
The bigger picture
The ADC field is experiencing explosive growth, with over a dozen approved drugs. New linker technologies like this expand the design space for next-generation targeted cancer therapies with better selectivity and fewer off-target effects.
Questions still open
- How does this linker's release kinetics compare to clinically approved ADC linkers?
- Can this scaffold accommodate a wider range of cytotoxic payloads?
- What is the in vivo therapeutic index of conjugates using this linker?
Common questions
What is a peptide-drug conjugate?
Why does the linker matter so much in cancer drug design?
Read the original research
Use of a Cyclic α-Alkylidene-β-Diketone as a Cleavable Linker Strategy for Antibody-Drug Conjugates.
Journal of the American Chemical Society, 146(34), 23717-23728
Citation
Tong, Juliana T W; Sarwar, Makhdoom; Ahangarpour, Marzieh; Hume, Paul A; Williams, Geoffrey M; Brimble, Margaret A; Kavianinia, Iman. (2024). Use of a Cyclic α-Alkylidene-β-Diketone as a Cleavable Linker Strategy for Antibody-Drug Conjugates.. Journal of the American Chemical Society, 146(34), 23717-23728. https://doi.org/10.1021/jacs.4c04567